LBS 009
Alternative Names: LBS-009Latest Information Update: 16 Jun 2024
Price :
$50 *
At a glance
- Originator Belite Bio
- Class Antihyperglycaemics; Hepatoprotectants; Small molecules
- Mechanism of Action RBP4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 29 May 2024 Preclinical trials in Non-alcoholic fatty liver disease in USA (PO) prior to May 2024 (Belite Bio pipeline, May 2024)
- 29 May 2024 Preclinical trials in Non-alcoholic steatohepatitis in USA (PO) Prior to May 2024 (Belite Bio pipeline, May 2024)
- 29 May 2024 Preclinical trials in Type 2 diabetes mellitus in USA (PO) Prior to May 2024 (Belite Bio pipeline, May 2024)